Repligen Q3-26 Earnings Call - REPLIGEN CORP

Financial Performance:

• Third quarter 2026 revenue reached a record $209 million, representing 12.5% organic growth and 11% reported year-over-year growth.
• Adjusted gross margin was 53%, a 30 basis point sequential decline due to product mix and inflation, though volume leverage and pricing provided support; full-year margin expansion remains on track for 110–160 basis points.
• Adjusted operating margin expanded 170 basis points year-over-year to 15.9%, driven by strong leverage and 5% adjusted operating expense growth.
• Adjusted net income was $30 million (up 16% YoY), while GAAP results included a $41 million non-cash intangible asset impairment unrelated to core operations.
• Adjusted EBITDA was $44 million (20.9% margin), and cash, cash equivalents, and marketable securities ended at $863 million.
• BioLife acquisition closed in October; $550 million deployed for the transaction, leaving a pro forma cash balance exceeding $300 million.

Guidance and Future Outlook:

• 2026 revenue guidance increased to $844–852 million (midpoint $848 million), assuming 14.5–15.5% reported growth and 12–13% organic growth.
• Updated 2026 adjusted EPS guidance raised to $2.25–$2.29 (midpoint), reflecting BioLife contribution and margin expansion.
• 2027 outlook targets reported revenue exceeding $1 billion, with management expecting to outpace a high-single-digit market growth rate by at least 500 basis points.
• BioLife is expected to contribute approximately $24 million in Q4 2026 and achieve at least 5 cents per share of accretion in 2027.
• Management anticipates full-year 2026 organic growth midpoint of 12–13%, narrowing the previous range to reflect prudent integration assumptions.

Business Segments and Product Lines:

• Filtration: Revenue declined 11% due to the PolyMEM divestiture, foreign exchange, and timing of capital equipment deliveries shifting to 2027; expected to be flat to slightly down for the full year.
• Chromatography: Revenue grew >50% driven by Opus columns and large-scale column demand; full-year growth expected at >30%.
• Proteins: Recorded >40% growth driven by ligands, growth factors, and resins; extended supply agreement with Ecolab; full-year growth expected in mid-teens.
• Analytics: Achieved a record quarter with 20% growth driven by consumables and services; USP Chapter 507 recognition of Solo VP Plus technology validated the platform.
• BioLife Acquisition: Expanded capabilities in cell therapy; initial integration focused on cost synergies (public company costs, leadership) and process improvements (cryo-store scrap rates).
• Services: Revenue grew >20% as the number of systems under contract increased nearly 40% year-to-date; services now represent 7% of revenue.

Market and Competitive Landscape:

• Capital equipment orders reached a five-year high in Q3, with the highest order intake in the franchise's history, though revenue recognition is delayed into 2027.
• China revenue grew >40% in Q3 and >50% year-to-date; government 5-year plan targets 20% CAGR through 2030.
• Emerging biotech demand remained healthy with high-teen year-to-date growth despite a difficult comparison.
• New modalities saw 30% growth in cell therapy and >25% growth in gene therapy; biosimilar inflection expected to drive future growth.
• Competitive advantage strengthening via USP Chapter 507 validation and high attachment rates of Flow VPX analytics to new systems (80% of recent sales).

Risks and Challenges:

• Capital equipment "tap" has opened slowly; customer decision-making velocity remains delayed, causing a disconnect between record orders and current revenue recognition.
• Inflationary pressures impacting margins, though offset by sourcing negotiations and automation initiatives.
• Regulatory uncertainty regarding future FDA approvals for cell and gene therapies could impact the 2027 market growth rate.
• Integration risks associated with combining Repligen and BioLife, including potential disruptions to cryo-store operations.
• One-time GAAP impairment of $41 million due to a failed intellectual property license agreement.

Management Commentary and Tone:

• Tone is highly confident and optimistic, describing the quarter as a "proof point" of the industry's next growth phase and the success of the diversified portfolio.
• Management expressed pride in outpacing market growth despite lapping strong prior-year results.
• Emphasis placed on the strategic fit of BioLife, noting a shared culture of innovation and immediate progress on synergy realization.
• Leadership highlighted the "Fit for Growth" transformation and AI modernization as key drivers for long-term margin expansion and productivity.

Analyst Questions and Answers:

• Integration Cadence: BioLife synergies are being realized faster than expected, with operating expense synergies largely captured; margin accretion expected to be >5 cents in 2027.
• Filtration Timing: The decline in filtration revenue was driven by timing of system deliveries pushed to 2027, despite record order intake; confidence remains high for a return to historical growth in 2027.
• Equipment Visibility: While order backlog is at record levels, revenue recognition is delayed due to slower customer decision-making; management views the current backlog as a precursor to a "gigantic" revenue unlock when the market fully opens.
• On-Shoring: On-shoring RFPs are increasing but have been delayed by 9–12 months relative to 2026 expectations; major orders and deliveries anticipated in 2027–2028.
• Biosimilars: Significant pickup in biosimilar applications for ATS (Advanced Therapeutics Services) and ATF; patent cliffs for major biologics are expected to drive demand over the next 2–3 years.
• Ecolab Partnership: Renewal of supply agreement signals strong momentum in the protein franchise, which has grown 34% year-to-date.

Other Key Points:

• Repligen is opening a new training and innovation center in South Korea to bolster its Asia-Pacific strategy.
• Analytics franchise is leveraging AI and digital twin capabilities, with significant traction from customers adopting process analytical technology (PAT).
• Management plans to invest in commercial resources and R&D in 2027 to accelerate growth, potentially achieving the 30% EBITA target earlier than 2030.
• The company is actively pursuing an integrated solution approach to support large-scale manufacturing expansion projects.
• Q3 represented the low point for gross margins in 2026, with expectations for full-year margin expansion to follow.